[2] As of 2019, tesofensine has been discontinued for the treatment of Alzheimer's and Parkinson's disease but is in phase III clinical trial for obesity.

[[13] cited in [14]] The revised IC50's would adequately explain the lack of efficacy in treating Parkinson's disease, i.e. insufficient DRI potency relative to the SERT and the NAT.

[13] Phase IIB trial (TIPO-1) results reported in The Lancet[19] showed levels of weight loss over a 6-month period that were significantly greater than those achieved with any other drugs available at the time.

All participants were instructed to follow a diet with a 300 kcal deficit and to increase their physical activity gradually to 30–60 minutes of exercise per day.

The weight loss seen in the Phase IIB trial was approximately double that produced by medications that had been approved (as of 2008) by the US Food and Drug Administration (FDA) for the treatment of obesity.

The most commonly reported side effects in the obese population were dry mouth, headache, nausea, insomnia, diarrhea and constipation.

The overall withdrawal rate due to adverse events in clinical trials in the obese population was 13% with tesofensine and 6% with placebo.